SYNODOS

Synodos is a first-of-its-kind Nuerofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis.

SYNODOS

Synodos is a first-of-its-kind neurofibromatosis research collaboration dedicated to defeating a variety of forms of neurofibromatosis. To date there are three Synodos efforts funded by Children’s Tumor Foundation (CTF) and supported by Sage. The Synodos model brings together a multidisciplinary team of scientists from world-class labs at academic and medical centers of excellence, who have pledged to work closely together – sharing information, datasets, results and more – at every step in research development, with the goal of speeding up the drug discovery process.

  • Synodos NF2 is the first of the Synodos efforts that studies the the rare genetic disorder neurofibromatosis type 2 (NF2) with the end goal of finding new approaches to the diagnosis and treatment of two primary NF2-related tumors: vestibular schwannoma and meningioma.
  • Synodos NF1 represents diverse approaches to pre-clinical drug discovery for plexiform neurofibromas that arise in NF1 patients.
  • Synodos LGG targets low-grade gliomas that arise in NF1 patients. Together these efforts will create a unified data repository of NF-related research that will be made available to the community to further the development of drugs to treat NF.

Learn more about Synodos on the CTF website.


Other Collaborative Science research studies

Accelerating Medicine Partnership in Alzheimer’s Disease

AMP-AD is a public private partnership designed to use systems biology to identify novel targets for AD treatment.

Learn More

The ICGC-TCGA Whole Genome Pan-Cancer Analysis Working Group

The Pan-Cancer Analysis of Whole Genomes (PCAWG) is an effort to combine all ICGC and TCGA whole genome sequencing data to collaboratively attain an integrated understanding of cancer by deriving insights across tumor types.

Learn More

SYNODOS

Synodos is a first-of-its-kind Nuerofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis.

Learn More